Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
08:05am, Wednesday, 11'th Feb 2026
NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Feb 2026
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
New Strong Sell Stocks for January 20th
10:15am, Tuesday, 20'th Jan 2026
DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of “Moderate Buy” from Analysts
03:28am, Monday, 08'th Dec 2025
Shares of Candel Therapeutics, Inc. (NASDAQ: CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
04:05pm, Monday, 17'th Nov 2025
NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Brokerages Set Candel Therapeutics, Inc. (NASDAQ:CADL) Target Price at $18.50
01:19am, Sunday, 16'th Nov 2025
Shares of Candel Therapeutics, Inc. (NASDAQ: CADL - Get Free Report) have received an average rating of "Moderate Buy" from the eight analysts that are currently covering the firm, Marketbeat.com repo
Candel Therapeutics highlights third quarter milestones across cancer immunotherapy pipeline
09:49am, Thursday, 13'th Nov 2025
Candel Therapeutics Inc (NASDAQ:CADL) reported encouraging clinical progress across its cancer immunotherapy pipeline, along with the release of its third quarter 2025 financial results. The company
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
08:25am, Thursday, 13'th Nov 2025
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostat
Candel Therapeutics to highlight immunotherapy advances at SITC 2025
09:54am, Tuesday, 04'th Nov 2025
Candel Therapeutics Inc (NASDAQ:CADL) will deliver three presentations at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). “Candel's presentations at SITC 2025 exe
NEEDHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunoth
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
08:05am, Monday, 03'rd Nov 2025
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics secures $130M to fund lead program – ICYMI
09:32am, Saturday, 18'th Oct 2025
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr. Paul Peter Tak talked with Proactive about the company's recently secured $130 million term loan facility with Trinity Capital.
Candel Therapeutics strengthens Research Advisory Board with appointment of immunology expert
08:42am, Thursday, 16'th Oct 2025
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Dr Bali Pulendran, a leading authority in systems immunology and vaccinology, to its Research Advisory Board. Dr Pulendran is the
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
08:05am, Thursday, 16'th Oct 2025
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics secures $130M loan to advance cancer therapy trials
08:49am, Tuesday, 14'th Oct 2025
Candel Therapeutics Inc (NASDAQ:CADL) said it has inked a five-year, $130 million term loan facility with Trinity Capital to strengthen its balance sheet and support late-stage development and potenti
